Venetoclax for patients with chronic lymphocytic leukaemia & small lymphocytic lymphoma
Venetoclax for patients with chronic lymphocytic leukaemia & small lymphocytic lymphoma.
Prof John Seymour, Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
Prof John Seymour discussed targeted therapies emerging for patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. He discussed a new class of drug venetoclax that interferes with apoptosis (cell death).
Prof Seymour discussed that antibodies are combined with new medication such as venetoclax. Venetoclax has been seen to work well with rituximab for over 2 years.
Venetoclax does come with side effects and he discussed how this can be managed, with gradual introduction to the patient. Other side effects include:
• Nausea
• Diarrahoea
• Lowered blood counts
• Infection
For more information please visit the Lymphoma Australia website:
www.lymphoma.org.au and resources: https://www.lymphoma.org.au/page/1218/fact-sheets
Lymphoma Resources:
o Lymphoma: what you need to know? (booklet)
o Living with CLL (booklet)
o Lymphoma/CLL subtypes
o Lymphoma Management
o Oral therapies and lymphoma/CLL
o Understanding Clinical Trials
o Emotional impact of lymphoma
Lymphoma Australia YouTube channel: https://www.youtube.com/user/LymphomaAustralia
“Lymphoma Down Under” private Facebook group; support for patients & carers affected by lymphoma/CLL
Lymphoma Care Nurses:
T: 1800 953 081
E: nurse@lymphoma.org.au
-
Category
No comments found